Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349557 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
A Phase 2 study, sponsored by Benaroya Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00349557: Completed Phase 2 study, sponsored by Benaroya Research Institute.
NCT00349557 is a Phase 2 study that has completed, run by Benaroya Research Institute. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00349557, a Phase 2 study, has completed, sponsored by Benaroya Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2 years).
Interventions
- DRUG bevacizumab, bicalutamide and goserelin
- PROCEDURE intensity modulated radiation therapy (IMRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00349557 record still lists
NCT00349557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which bevacizumab, bicalutamide and goserelin is the first listed.
NCT00349557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00349557 about?
NCT00349557 is a clinical study titled "Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer". The purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2 years).
What is the current status of trial NCT00349557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2006-04.
What interventions are being tested in trial NCT00349557?
The interventions under investigation include: bevacizumab, bicalutamide and goserelin (DRUG), intensity modulated radiation therapy (IMRT) (PROCEDURE).
Who is sponsoring clinical trial NCT00349557?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00349557's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia